Study Design of the PERSEUS Trial

Opinion
Video

Hematologic oncology specialists provide an overview of the study design of the PERSEUS trial and outline the role of MRD negativity in the treatment of patients with multiple myeloma.

Video content above is prompted by the following question(s):

  • What is minimal residual disease (MRD) and why is achieving MRD negativity significant in the treatment of multiple myeloma?
Recent Videos
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Related Content
More than 70% of patients achieve an objective response with isatuximab plus pomalidomide and dexamethasone in the phase 2 EAE115 trial.

Isatuximab Combo Shows Preliminary Activity in Pretreated Multiple Myeloma

Russ Conroy
June 24th 2025
Article

More than 70% of patients achieve an objective response with isatuximab plus pomalidomide and dexamethasone in the phase 2 EAE115 trial.

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma

Samantha Shenoy, NP, MSN
October 14th 2024
Podcast

Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.

Mezigdomide with dexamethasone and bortezomib or carfilzomib led to a median PFS exceeding 1 year across 3 cohorts in those with relapsed/refractory MM.

Mezigdomide Regimens Show Promise in Pretreated R/R Multiple Myeloma

Tim Cortese
June 19th 2025
Article

Mezigdomide with dexamethasone and bortezomib or carfilzomib led to a median PFS exceeding 1 year across 3 cohorts in those with relapsed/refractory MM.

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma

James R. Berenson, MD, FACP
September 30th 2024
Podcast

James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.

Elranatamab Triplet Induces Early and Deep Responses in Newly Diagnosed MM

Elranatamab Triplet Induces Early and Deep Responses in Newly Diagnosed MM

Ariana Pelosci
June 16th 2025
Article

The MagnetisMM-6 trial results showed that elranatamab plus daratumumab and lenalidomide yielded an ORR of 97.3% in transplant-ineligible multiple myeloma.

Similar response rates and safety profiles were observed with subcutaenous and intravenous isatuximab in the phase 3 IRAKLIA study.

Subcutaneous Isatuximab Shows Noninferior Efficacy in Multiple Myeloma

Kristi Rosa
June 16th 2025
Article

Similar response rates and safety profiles were observed with subcutaenous and intravenous isatuximab in the phase 3 IRAKLIA study.